Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Chronic kidney disease

Reductions in FGF-23 levels associated with improved outcomes

Nature Reviews Nephrology volume 11, pages 572–573 (2015)Cite this article

Subjects

Elevated levels of fibrobast growth factor 23 (FGF-23) are associated with cardiovascular and all-cause mortality in patients with kidney disease. A secondary analysis of the EVOLVE trial reports that cinacalcet-induced reductions in FGF-23 were associated with a reduced risk of cardiovascular events in patients with secondary hyperparathyroidism on dialysis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Collins, A. J. et al. United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease. Kidney Int. 5, 2–7 (2011).

    Article  Google Scholar 

  2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD–MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int. Suppl. 113, S1–S130 (2009).

  3. Kendrick, J. et al. FGF-23 associated with death, cardiovascular events, and initiation of chronic dialysis. J. Am. Soc. Nephrol. 22, 1913–1922 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Moe, S. M. et al. Cinacalcet, FGF23 and cardiovascular disease in hemodialysis: the EVOLVE Trial. Circulation http://dx.doi.org/10.1161/CIRCULATIONAHA.114.013876.

  5. Gutierrez, O. M. et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J. Am. Soc. Nephrol. 16, 2205–2215 (2005).

    Article  CAS  PubMed  Google Scholar 

  6. Faul, C. et al. FGF23 induces left ventricular hypertrophy. J. Clin. Inv. 121, 4393–4408 (2011).

    Article  CAS  Google Scholar 

  7. Hsu, H. J. & Wu, M. S. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am. J. Med. Sci. 337, 115–122 (2009).

    Article  Google Scholar 

  8. Evenepoel, P., Rodriguez, M. & Ketteler, M. Laboratory abnormalities in CKD-MBD: markers, predictors, or mediators of disease? Semin. Nephrol. 34, 151–163 (2014).

    Article  CAS  PubMed  Google Scholar 

  9. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 42, S1–S201 (2003).

  10. Wetmore, J. B., Liu, S., Krebil, R., Menard, R. & Quarles, L. D. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin. J. Am. Soc. Nephrol. 5, 110–116 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Renal Section, Medicine Service, Denver VA Medical Center, 1055 Clermont Street, Denver, CO 80220, USA.,

    Anna Jovanovich

  2. Division of Renal Diseases and Hypertension, University of Colorado Denver Anschutz Medical Center, 13199 East Montview Boulevard, Suite 495, Aurora, CO 80045, USA.,

    Michel Chonchol

Authors
  1. Anna Jovanovich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michel Chonchol
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michel Chonchol.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jovanovich, A., Chonchol, M. Reductions in FGF-23 levels associated with improved outcomes. Nat Rev Nephrol 11, 572–573 (2015). https://doi.org/10.1038/nrneph.2015.125

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2015.125

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing